kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human HVEM/TNFRSF14 Protein, Fc Tag, 100µg  

Recombinant human HVEM/TNFRSF14 Protein, Fc Tag, 100µg

Recombinant Human HVEM /TNFRSF14 Protein, Pro37-Val202, produced in human 293 cells (HEK293), Fc Tag (MALS verified)

recombinant, human protein, TNFRSF14, ATAR, HVEA, HVEM, LIGHTR, TR2, CD270, herpesvirus entry mediator

More details


Availability: within 7 days

390,00 €

Herpesvirus entry mediator (HVEM), also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFß (lymphotoxin a) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTßR, the receptor for lymphotoxin aß heterotrimer. The role of the HVEM LIGHT /LTß receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

Recombinant Human HVEM /TNFRSF14 Protein, Fc Tag (HVM-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 39 - Val 202 (Accession # NP_003811.2).
Predicted N-terminus: Leu 39

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 43.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "The BTLA-HVEM complex - The future of cancer immunotherapy"
Wojciechowicz, Spodzieja, Wardowska
Eur J Med Chem (2024) 268, 116231
(2) "LIGHT signaling through LTβR and HVEM in keratinocytes promotes psoriasis and atopic dermatitis-like skin inflammation"
Gupta, Figueroa, Fung et al
J Autoimmun (2024) 144, 103177
(3) "The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity"
Cheng, Weng, Jia et al
Front Pharmacol (2022) 13, 977025
Showing 1-3 of 998 papers.